Back to Journals » Drug Design, Development and Therapy » Volume 14

Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases

Authors Liu H, Yang J, Yang W, Hu S, Wu Y, Zhao B, Hu H, Du S

Received 29 November 2019

Accepted for publication 28 January 2020

Published 7 February 2020 Volume 2020:14 Pages 551—565


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo

Hai Liu,1,2 Jianqiong Yang,3 Wanqing Yang,1 Shaonan Hu,1 Yali Wu,1 Bo Zhao,1 Haiyan Hu,1 Shouying Du1

1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2College of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, People’s Republic of China; 3Department of Clinical Research Center, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People’s Republic of China

Correspondence: Shouying Du
School of Chinese Materia Medica, Beijing University of Chinese Medicine, 11 North 3rd Ring East Road, Chaoyang District, Beijing, People’s Republic of China
Tel +86 17812165051
Fax +86 10 64286231

Abstract: Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development.

Keywords: notoginsenoside (NG)-R1, Panax notoginseng, micro-circulatory hemostasis, permeability, bioavailability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]